[SCHEDULE 13G/A] Calidi Biotherapeutics, Inc. SEC Filing
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 117,368 shares of Calidi Biotherapeutics common stock, representing 4.99% of the class. The reported position reflects shared voting and shared dispositive power of the shares rather than sole control. Armistice Capital serves as investment manager to a Master Fund that directly holds the shares and, under an investment management agreement, exercises voting and investment power over them; the Master Fund disclaims direct beneficial ownership because it cannot vote or dispose of the shares independently. The filing states the securities are held in the ordinary course of business and not for the purpose of changing control.
Armistice Capital, LLC e Steven Boyd dichiarano la propriet脿 beneficiaria di 117.368 azioni di azioni ordinarie di Calidi Biotherapeutics, pari a il 4,99% della categoria. La posizione segnalata riflette la condivisione del diritto di voto e del potere dispositvo sulle azioni anzich茅 il controllo esclusivo. Armistice Capital agisce come gestore degli investimenti di un Master Fund che detiene direttamente le azioni e, in base a un contratto di gestione degli investimenti, esercita su di esse il potere di voto e di investimento; il Master Fund dichiara di non essere proprietario beneficiario diretto perch茅 non pu貌 votare o disporre delle azioni in modo indipendente. La comunicazione precisa che i titoli sono detenuti nell'ordinaria attivit脿 d'impresa e non al fine di modificare il controllo.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiaria de 117.368 acciones de acciones ordinarias de Calidi Biotherapeutics, que representan el 4,99% de la clase. La posici贸n declarada refleja el poder compartido de voto y disposici贸n sobre las acciones en lugar de un control exclusivo. Armistice Capital act煤a como gestor de inversiones de un Master Fund que posee directamente las acciones y, en virtud de un acuerdo de gesti贸n de inversiones, ejerce sobre ellas el poder de voto y de inversi贸n; el Master Fund renuncia a la condici贸n de propietario beneficiario directo porque no puede votar ni disponer de las acciones de forma independiente. La presentaci贸n indica que los valores se mantienen en el curso normal del negocio y no con la finalidad de cambiar el control.
Armistice Capital, LLC鞕� Steven Boyd電� Calidi Biotherapeutics 氤错喌欤� 117,368欤�鞚� 鞁れ唽鞙犼秾鞚� 氤搓碃頃橂┌, 鞚措姅 頃措嫻 欤检嫕鞚� 4.99%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 氤挫湢電� 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞚� 氚橃榿頃橂┌ 雼弲 韱奠牅電� 鞎勲嫏雼堧嫟. Armistice Capital鞚� 欤检嫕鞚� 歆侅爲 氤挫湢頃� 毵堨姢韯� 韼�霌滌潣 韴瀽 毵る媹鞝�搿滌劀 韴瀽甏�毽硠鞎届棎 霐半澕 頃措嫻 欤检嫕鞐� 雽�頃� 鞚橁舶甓岅臣 韴瀽甓岇潉 頄夓偓頃╇媹雼�; 毵堨姢韯� 韼�霌滊姅 欤检嫕鞚� 霃呾瀽鞝侅溂搿� 鞚橁舶頃橁卑雮� 觳橂秳頃� 靾� 鞐嗞赴 霑岆鞐� 歆侅爲鞝侅澑 鞁れ唽鞙犼秾鞚� 攵�鞚疙暕雼堧嫟. 鞝滌稖靹滊電� 鞚� 歃濌秾霌れ澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 氤�瓴届潉 氇╈爜鞙茧 頃橃 鞎婌晿雼り碃 氇呾嫓頃╇媹雼�.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 117 368 actions d'actions ordinaires de Calidi Biotherapeutics, repr茅sentant 4,99 % de la cat茅gorie. La position signal茅e refl猫te le pouvoir de vote et le pouvoir de disposition partag茅s sur les actions plut么t qu'un contr么le exclusif. Armistice Capital agit en tant que gestionnaire d'investissement d'un Master Fund qui d茅tient directement les actions et, en vertu d'un contrat de gestion d'investissement, exerce sur celles-ci le pouvoir de vote et d'investissement ; le Master Fund d茅cline la qualit茅 de propri茅taire b茅n茅ficiaire direct car il ne peut pas voter ni disposer des actions de mani猫re ind茅pendante. Le d茅p么t pr茅cise que les titres sont d茅tenus dans le cours normal des affaires et non dans le but de modifier le contr么le.
Armistice Capital, LLC und Steven Boyd melden die wirtschaftliche Eigent眉merschaft von 117.368 Aktien der Stammaktien von Calidi Biotherapeutics, was 4,99 % der Klasse entspricht. Die gemeldete Position spiegelt gemeinsames Stimm- und Verf眉gungsrecht an den Aktien wider und nicht die alleinige Kontrolle. Armistice Capital fungiert als Investmentmanager eines Master-Fonds, der die Aktien direkt h盲lt und gem盲脽 einem Investmentmanagementvertrag Stimm- und Anlageentscheidungen trifft; der Master-Fonds weist direkte wirtschaftliche Eigent眉merschaft zur眉ck, da er die Aktien nicht eigenst盲ndig stimmen oder ver盲u脽ern kann. Die Meldung gibt an, dass die Wertpapiere im ordentlichen Gesch盲ftsverkehr gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern.
- Full disclosure of position at 117,368 shares (4.99%), providing transparency to the market
- Clear ownership structure showing Armistice Capital's managerial authority and the Master Fund as the direct holder
- Certification of passive intent stating shares are held in the ordinary course and not to influence control
- None.
Insights
TL;DR Reporting shows a sub-5% position held through an investment manager, indicating disclosure rather than a control intent.
Armistice's 4.99% stake is large enough to warrant Schedule 13G disclosure but below thresholds that typically indicate activist intent. Shared voting and dispositive power via the investment manager structure means decision authority rests with Armistice, not the Master Fund. The filing's certification that the holdings are in the ordinary course and not for control reduces the likelihood of imminent corporate governance action. For investors, this is transparency on ownership without a material change to control dynamics.
TL;DR The filing documents passive ownership under an investment management arrangement and contains the standard managerial disclaimers.
The Schedule 13G identifies shared voting/dispositive power allocated to Armistice Capital and disclaimed direct ownership by the Master Fund, a common structure when an investment manager controls voting. The explicit statement that shares were not acquired to influence control and are held in the ordinary course aligns with the passive investor classification. There are no governance red flags such as coordinated group action or explicit control intentions disclosed.
Armistice Capital, LLC e Steven Boyd dichiarano la propriet脿 beneficiaria di 117.368 azioni di azioni ordinarie di Calidi Biotherapeutics, pari a il 4,99% della categoria. La posizione segnalata riflette la condivisione del diritto di voto e del potere dispositvo sulle azioni anzich茅 il controllo esclusivo. Armistice Capital agisce come gestore degli investimenti di un Master Fund che detiene direttamente le azioni e, in base a un contratto di gestione degli investimenti, esercita su di esse il potere di voto e di investimento; il Master Fund dichiara di non essere proprietario beneficiario diretto perch茅 non pu貌 votare o disporre delle azioni in modo indipendente. La comunicazione precisa che i titoli sono detenuti nell'ordinaria attivit脿 d'impresa e non al fine di modificare il controllo.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiaria de 117.368 acciones de acciones ordinarias de Calidi Biotherapeutics, que representan el 4,99% de la clase. La posici贸n declarada refleja el poder compartido de voto y disposici贸n sobre las acciones en lugar de un control exclusivo. Armistice Capital act煤a como gestor de inversiones de un Master Fund que posee directamente las acciones y, en virtud de un acuerdo de gesti贸n de inversiones, ejerce sobre ellas el poder de voto y de inversi贸n; el Master Fund renuncia a la condici贸n de propietario beneficiario directo porque no puede votar ni disponer de las acciones de forma independiente. La presentaci贸n indica que los valores se mantienen en el curso normal del negocio y no con la finalidad de cambiar el control.
Armistice Capital, LLC鞕� Steven Boyd電� Calidi Biotherapeutics 氤错喌欤� 117,368欤�鞚� 鞁れ唽鞙犼秾鞚� 氤搓碃頃橂┌, 鞚措姅 頃措嫻 欤检嫕鞚� 4.99%鞐� 頃措嫻頃╇媹雼�. 氤搓碃霅� 氤挫湢電� 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞚� 氚橃榿頃橂┌ 雼弲 韱奠牅電� 鞎勲嫏雼堧嫟. Armistice Capital鞚� 欤检嫕鞚� 歆侅爲 氤挫湢頃� 毵堨姢韯� 韼�霌滌潣 韴瀽 毵る媹鞝�搿滌劀 韴瀽甏�毽硠鞎届棎 霐半澕 頃措嫻 欤检嫕鞐� 雽�頃� 鞚橁舶甓岅臣 韴瀽甓岇潉 頄夓偓頃╇媹雼�; 毵堨姢韯� 韼�霌滊姅 欤检嫕鞚� 霃呾瀽鞝侅溂搿� 鞚橁舶頃橁卑雮� 觳橂秳頃� 靾� 鞐嗞赴 霑岆鞐� 歆侅爲鞝侅澑 鞁れ唽鞙犼秾鞚� 攵�鞚疙暕雼堧嫟. 鞝滌稖靹滊電� 鞚� 歃濌秾霌れ澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 氤�瓴届潉 氇╈爜鞙茧 頃橃 鞎婌晿雼り碃 氇呾嫓頃╇媹雼�.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 117 368 actions d'actions ordinaires de Calidi Biotherapeutics, repr茅sentant 4,99 % de la cat茅gorie. La position signal茅e refl猫te le pouvoir de vote et le pouvoir de disposition partag茅s sur les actions plut么t qu'un contr么le exclusif. Armistice Capital agit en tant que gestionnaire d'investissement d'un Master Fund qui d茅tient directement les actions et, en vertu d'un contrat de gestion d'investissement, exerce sur celles-ci le pouvoir de vote et d'investissement ; le Master Fund d茅cline la qualit茅 de propri茅taire b茅n茅ficiaire direct car il ne peut pas voter ni disposer des actions de mani猫re ind茅pendante. Le d茅p么t pr茅cise que les titres sont d茅tenus dans le cours normal des affaires et non dans le but de modifier le contr么le.
Armistice Capital, LLC und Steven Boyd melden die wirtschaftliche Eigent眉merschaft von 117.368 Aktien der Stammaktien von Calidi Biotherapeutics, was 4,99 % der Klasse entspricht. Die gemeldete Position spiegelt gemeinsames Stimm- und Verf眉gungsrecht an den Aktien wider und nicht die alleinige Kontrolle. Armistice Capital fungiert als Investmentmanager eines Master-Fonds, der die Aktien direkt h盲lt und gem盲脽 einem Investmentmanagementvertrag Stimm- und Anlageentscheidungen trifft; der Master-Fonds weist direkte wirtschaftliche Eigent眉merschaft zur眉ck, da er die Aktien nicht eigenst盲ndig stimmen oder ver盲u脽ern kann. Die Meldung gibt an, dass die Wertpapiere im ordentlichen Gesch盲ftsverkehr gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern.
FAQ
How many Calidi Biotherapeutics (CLDI) shares does Armistice Capital report owning?
What percentage of CLDI does the reported position represent?
Who holds voting and dispositive power over the reported CLDI shares?
Is the ownership reported as intended to influence control of CLDI?
Who is the direct holder of the shares according to the filing?
